Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06700070 · ClinicalTrials.gov registry record · Early Phase 1
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
A Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer, sponsored by Pure Biologics S.A..
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06700070 is a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer that is actively recruiting participants, run by Pure Biologics S.A.. The registered enrollment target is 12 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06700070, a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Pure Biologics S.A..
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantities via the CIVO device.
Conditions Studied
Interventions
- DRUG PBA-0111
Study Locations (1)
Louisiana
- LSU Health Sciences Center - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2025-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06700070
The ClinicalTrials.gov registry entry for NCT06700070 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (90% lower). The listed sponsor is Pure Biologics S.A., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which PBA-0111 is the first listed.
NCT06700070 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT06700070 about?
NCT06700070 is a clinical study titled "A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors". This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantities via the CIVO device.
What is the current status of trial NCT06700070?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2025-03-27. Estimated completion is 2025-12.
What conditions does trial NCT06700070 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Soft Tissue Sarcoma Adult.
What interventions are being tested in trial NCT06700070?
The interventions under investigation include: PBA-0111 (DRUG).
Who is sponsoring clinical trial NCT06700070?
This trial is sponsored by Pure Biologics S.A., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06700070 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
RECRUITING · Early Phase 1
-
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
RECRUITING · Early Phase 1
-
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
RECRUITING · Early Phase 1
-
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
RECRUITING · Early Phase 1
-
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
RECRUITING · Early Phase 1
-
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
COMPLETED · Early Phase 1
Explore more on PlainTrial
Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
Triple Negative Breast Cancer
All registered trials for this condition
Louisiana
All trials with a study site in Louisiana
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.